More

    Intas Pharmaceuticals under FDA scrutiny over ‘cascade of failure’ in oversight of GMP documents – Endpoints News


    Endpoints founder John Carroll sat down with ARCH managing director Robert Nelsen during JP Morgan to talk about innovation, what’s getting funded and what’s ahead in 2023. This transcript has been edited for brevity and clarity.

    John Carroll:

    I’m here with Bob Nelsen, one of the co-founders of ARCH. Bob and I talk every now and then, usually about one of his latest crazy ideas that he’s invested a tremendous sum of money in. And I wanted to use this as an opportunity to talk about what he is about. Fascinating stuff. I did a little bit of research, not a lot, but I went back to Matt Herper’s article in 2016, when Leroy Hood described you as a genius at getting companies like Illumina started. And you’ve done a whole variety of different things. You were talking about getting involved in Alnylam, and you were talking about you being involved in Juno, one of the original CAR-T companies that was out there, Denali, Vir, Resilience today is in the news; Mubadala is financing a new manufacturing plant in the United Arab Emirates. Lots going on in what you could call a very interesting market, but I wanted to start back at the beginning, because I think that’s really cool. You got your MBA in 1986.

    Endpoints Premium

    Premium subscription required

    Unlock this article along with other benefits by subscribing to one of our paid plans.




    Source link

    Latest articles

    Related articles

    Discover more from Blog | News | Travel

    Subscribe now to keep reading and get access to the full archive.

    Continue reading